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Calcium channel blockersThe treatment with the chemotherapeutic agent paclitaxel produces a painful peripheral neuropathy, and
is associated with an acute pain syndrome in a clinically signiﬁcant number of patients. However, no standard
therapy has been established to manage the acute pain or the chronic neuropathic pain related to paclitaxel. In
the present study, we evaluated the analgesic potential of two N-type voltage-gated calcium channel (VGCC)
blockers, ω-conotoxin MVIIA and Phα1β, on acute and chronic pain induced by paclitaxel. Adult male
rats were treated with four intraperitoneal injections of paclitaxel (1 + 1 + 1 + 1 mg/kg, in alternate days)
and the development of mechanical hyperalgesia was evaluated 24 h (acute painful stage) or 15 days (chronic
painful stage) after the ﬁrst paclitaxel injection. Not all animals showed mechanical hyperalgesia 24 h after
the ﬁrst paclitaxel injection, but those that showed developed a more intense mechanical hyperalgesia at
the chronic painful stage. Intrathecal administration (i.t.) of ω-conotoxin MVIIA (3–300 pmol/site) or Phα1β
(10–300pmol/site) reduced themechanical hyperalgesia either at the acute or at the chronic painful stage induced
by paclitaxel. When administered at the acute painful stage, ω-conotoxin MVIIA (300 pmol/site, i.t.) and Phα1β
(300 pmol/site, i.t.) prevented the worsening of chronic mechanical hyperalgesia. Furthermore, Phα1β (30-
300 pmol/site, i.t.) elicited less adverse effects than ω-conotoxin MVIIA (10-300 pmol/site, i.t.). Taken together,
our data evidence the involvement of N-type VGCC in pain sensitization induced by paclitaxel and point out the
potential of Phα1β as a safer alternative than ω-conotoxin MVIIA to treat the pain related to paclitaxel.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Paclitaxel is a chemotherapeutic agent commonly used in solid
tumors (Rowinsky et al., 1993; Polomano et al., 2001). The main side
effect associated with long-term use of paclitaxel is a chronic periph-
eral neuropathy, characterized by mechanical hyperalgesia, tingling
and numbness affecting the distal extremities (Rowinsky et al., 1993;
Forsyth et al., 1997; Dougherty et al., 2004; Woolf et al., 2008).
The onset of sensory symptoms during paclitaxel treatment usually
leads to a reduction in the dose or interruption of therapy, which
can negatively affect cancer therapy outcomes (Polomano and Bennett,
2001; Dougherty et al., 2004). Moreover, it has been recently reporteda Catarina, CampusUniversitário
e Farmacologia, Santa Catarina,
+55 48 3337 5479.
. Dalmolin),
ghts reserved.that paclitaxel is also associated with an acute pain syndrome that
develops in the ﬁrst days of treatment, and affects a large proportion of
patients (Loprinzi et al., 2007, 2011; Reeves et al., 2012). Furthermore,
the acute pain experienced by some patients in the beginning of the
treatment with paclitaxel appears to be somehow related to the severity
of the later neuropathic pain (Loprinzi et al., 2011; Reeves et al., 2012).
The chronic neuropathic pain induced by paclitaxel has been studied
using animal models (Polomano et al., 2001; Naguib et al., 2012),
however, to our knowledge, no preclinical studies have addressed the
acute pain induced by paclitaxel or its inﬂuence in chronic neuropathic
pain.
Currently, there are no standard therapies to prevent or minimize
the pain related to paclitaxel (Rowinsky et al., 1993; Gordon et al.,
1997; Wasserheit et al., 1996; Loprinzi et al., 2011; Reeves et al.,
2012). Nevertheless, several lines of evidence suggest the involvement
of voltage-gated calcium channels (VGCC) in pain arising from nerve
damage (Piekarz et al., 2012; Arcos et al., 2013; Kukkar et al., 2013),
including those induced by chemotherapeutic agents (Flatters and
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Kawakami et al., 2012). Furthermore, a N-type VGCC blocker peptide
derived from the venom of the cone snail Conus magus, the ω-conotoxin
MVIIA, had its synthetic form, ziconotide, recently approved for the
treatment of severe chronic pain, including neuropathic pain refractory
to other therapies (Staats et al., 2004; Prommer, 2006). However,
whether ziconotide alleviates the pain related to paclitaxel treatment is
yet to be investigated.
The clinical use of ziconotide, despite having conﬁrmed the good
analgesic efﬁcacy of ω-conotoxin MVIIA, has revealed to cause serious
adverse effects (Penn and Paice, 2000; Rauck et al., 2009; Achim et al.,
2010; Maier et al., 2011). We have been studied the analgesic potential
of a peptide toxin isolated from the venom of the Brazilian spider
Phoneutria nigriventer, named Phα1β, which inhibits VGCC, mainly the
N-type calcium currents (Vieira et al., 2005) in several animal models of
pain (Souza et al., 2008; de Souza et al., 2011, 2013; Castro-Junior et al.,
2013; Rigo et al., 2013). The Phα1β has shown antinociceptive effect
with a larger therapeutic window when comparing to ω-conotoxin
MVIIA (Souza et al., 2008; Castro-Junior et al., 2013; Rigo et al., 2013).
The primary goal of the present study was evaluate the analgesic
potential of ω-conotoxin MVIIA and Phα1β in the acute and chronic
neuropathic pain induced by paclitaxel. We showed that both VGCCs
reduced the acute and chronic mechanical hyperalgesia induced by
paclitaxel, but Phα1β produced less adverse effects than ω-conotoxin
MVIIA. In addition, we described a positive relation between the
development of acute pain and the degree of chronic neuropathic pain
induced by paclitaxel that can be controlled by spinal injection of both
VGCC blockers.
2. Materials and methods
2.1. Animals
Male adult Wistar rats weighing 250–300 g were used. All experi-
mental procedureswere approved by the ethics committee of the Federal
University of Santa Maria (process number: 23081.005024/2010-88),
and were carried out in accordance with the guidelines for the care
of laboratory animals and the ethical guidelines for investigations of
experimental pain in conscious animals (Zimmermann, 1983).
2.2. Drugs
Phα1β was puriﬁed from the venom of the Brazilian spider
P. nigriventer, as previously described (Cordeiro et al., 1993). The N-type
VGCC blockerω-conotoxinMVIIA was purchased from Latoxan (Valence,
France). Phα1β and ω-conotoxin MVIIA were dissolved in phosphate-
buffer saline (PBS; pH7.4). Paclitaxel (6mg/mL paclitaxel in Cremophor
EL and dehydrated ethanol) was purchased from Glenmark (Buenos
Aires, Argentina), and was dissolved in saline solution (NaCl, 0.9%).
2.3. Paclitaxel-induced acute and chronic pain model
Different group of rats received one or four intraperitoneal (i.p.)
injections of paclitaxel (1mg/kg), injected on alternate days (Polomano
et al., 2001). Acute pain was evaluated from 24 to 72 h after a single
injection of paclitaxel. Chronic pain was evaluated at 7, 15, 22, and
30days after the ﬁrst of four paclitaxel injections. Acute pain and chronic
painwere evaluated using the von Frey test, whichmeasuresmechanical
sensitivity. Mechanical hyperalgesia was deﬁned as a reduction of the
baseline paw withdrawal threshold of ≥50% after paclitaxel treatment.
2.4. Behavioral tests
2.4.1. Von Frey test
Mechanical threshold wasmeasured by applying von Frey ﬁlaments
on the plantar surface (sciatic nerve territory) of the rat's hindpaw,using the up–down method, as described previously (Chaplan et al.,
1994; Dixon, 1980). Brieﬂy, rats were ﬁrst acclimatized (1–2 h) in
individual clear Plexiglas boxes on an elevated wire mesh platform to
allow access to the plantar surface of the hind paws. Von Frey ﬁlaments
of increasing stiffness (6–100 g) were applied to the hind paw plantar
surface of the animalswith a pressure high enough to bend theﬁlament.
The absence of a paw lifting after 5 s led to the use of the next ﬁlament
with increasing weight, whereas paw lifting indicated a positive
response and led to the use of the next weaker ﬁlament. This paradigm
continued for a total of 6 measurements, including the one before the
ﬁrst paw-lifting response had beenmade, or until 4 consecutive positive
or 4 consecutive negative responses occurred. The 50% mechanical
paw withdraw threshold (PWT) response was then calculated from
the resulting scores as described previously by Dixon. The PWT was
expressed in grams (g).2.4.2. Adverse effects assessment
Adverse effects elicited by the treatments, such as serpentine-like tail
movement, body shaking and allodynia were assessed and quantiﬁed
using a 7-point scale, as previously described (Smith et al., 2002;
Malmberg and Yaksh, 1994).2.5. Experimental design
Theω-conotoxin MVIIA and Phα1βwere administered by intrathecal
(i.t.) route, as previously described (Dalmolin et al., 2011).
First, we evaluated the time-course of paclitaxel-induced acute and
chronic pain in two separated group of rats. In one group of rats, the
mechanical hyperalgesia was evaluated from 24 to 72 h after a single
injection of paclitaxel (1mg/kg, i.p.). In another group, rats received 4
injections of paclitaxel (1 + 1 + 1 + 1 mg/kg, i.p., in alternate days)
and after 7, 15, 22, and 30 days of the ﬁrst paclitaxel injection they
had their mechanical threshold examined.
Next, the time-course and the dose–response curve of antinociceptive
and adverse effects caused by i.t. treatment with ω-conotoxin MVIIA
(3–300 pmol/site) and by Phα1β (10–300 pmol/site) were evaluated
on acute pain (24 h after a single injection of paclitaxel) and chronic
neuropathic pain (15 days after the ﬁrst injection, in rats receiving 4
paclitaxel injections) induced by paclitaxel, in separated group of rats.
The next step was to investigate whether N-type VGCC blockade in
the acute painful stage affects the mechanical hyperalgesia in the
chronic painful stage. In brief, rats had their mechanical sensitivity
evaluated before and 24 h after the ﬁrst of four paclitaxel injections
(1 mg/kg, i.p.). Those rats that showed mechanical hyperalgesia
(reduction of the baseline PWT≥ 50%), were considered as part of the
group that developed acute pain, called acute pain affected group. The
rats that did not show mechanical hyperalgesia were classiﬁed as
acute pain non-affected group. Once the mechanical hyperalgesia
was established, the acute pain affected group was treated with PBS
(10 μl/site, i.t.), Phα1β (300 pmol/site, i.t.), or ω-conotoxin MVIIA
(300 pmol/site, i.t.) and evaluated from 15 to 360min post-treatment
in the von Frey test. Then, both acute pain affected and non-affected
groups continued receiving the next three paclitaxel injections in
alternate days, and had their mechanical sensibility re-evaluated
15 days after the ﬁrst injection, at the chronic painful stage. At this
stage, those rats showing mechanical hyperalgesia were treated with
PBS (10 μl/site, i.t.), Phα1β (300 pmol/site, i.t.), or ω-conotoxin MVIIA
(30 pmol/site, i.t.), and had their mechanical threshold evaluated from
15 to 360min. A schematic representation of the experimental design
can be found in Fig. 1.
In all experiments, the rats were randomly assigned to individual
experimental groups and the subsequent behavioral tests were
performed by an experimenter blind to the treatment conditions. Each
experiment was performed at least two times.
Fig. 1. Schematic representation of experimental design.
Fig. 2. Time-course of paclitaxel-induced acute and chronic mechanical hyperalgesia.
Time-course of mechanical hyperalgesia induced by a single injection of paclitaxel (PAC
- 1 mg/kg, i.p., indicate by the arrow) (A) and by four injections of paclitaxel in alternate
days (PAC - 1+1+1+1 mg/kg, indicated by arrows) (B). The effects are expressed as
PWT (g). B in the x axis denotes the baseline PWT before paclitaxel treatment. Each
point represents the mean of 5-8 rats, and vertical lines show the SEM. Statistical analysis
was performed using 2-way analysis of variance (ANOVA) followed by Bonferroni’s
posttest; ⁎⁎P b 0.01 and ⁎⁎⁎Pb 0.001 denote the signiﬁcance level in comparison to
saline-treated group (control group).
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Statistical analysiswas performedusingGraphPadPrismVersion 5.01.
Data were analyzed using a Student's t-test, and one-way or two-way
analysis of variance (ANOVA), followed by Bonferroni or Student–
Newman–Keuls (SNK) tests when appropriate. Adverse effects were
analyzed by Kruskal–Wallis followed by Dunn's test, when appropriate.
For analysis of proportions, the χ2 test was used. The effective dose 50%
(ED50) and the toxic dose 50% (TD50) values were calculated by non-
linear regression using a dose–response equation adjusted to provide
the best description of the values of the individual experiments. Values
of Pb0.05 were considered signiﬁcant.
The results are presented as mean ± standard error (PWT), as
median ± interquartile range (adverse effect scores), or as geometric
means accompanied by their respective 95% conﬁdence limits (ED50
and TD50).
3. Results
3.1. Antinociceptive effect of ω-conotoxin MVIIA and Phα1β on acute and
chronic pain induced by paclitaxel
The effect of i.t. administration ofω-conotoxin MVIIA and Phα1β on
the mechanical hyperalgesia induced by a single injection or by 4
injections of paclitaxel (1 mg/kg, i.p) was evaluated in rats. A single
injection of paclitaxel (1 mg/kg, i.p.) induced acute mechanical
hyperalgesia (reduction of PWT from 67.1 ± 10.6 g to 15.4 ± 4.0 g;
P b 0.01, 2-way ANOVA) at 24 h, that was no longer detected at 48 h
(Fig. 2A). The PWT of rats injectedwith saline (control group) remained
unchanged (64.5±11.5g at baseline and 51.7±12.2g 24h post-saline
injection). Four injections of paclitaxel produced a further reduction in
the mechanical threshold of rats, observed from 7 to 30 days after the
beginning of the treatment, reaching the maximum effect at day 15
(reduction of PWT from 50.2 ± 7.6 g to 9.9 ± 1.1 g; P b 0.001, 2-way
ANOVAFig. 2B). No difference was found in control group (Fig. 2B).
Therefore, the effects of ω-conotoxin MVIIA and Phα1β on paclitaxel-
induced acute and chronic pain were evaluated after 24h (acute painful
stage) or 15 days of the ﬁrst paclitaxel injection (chronic painful stage).
When tested at acute painful stage, administration of ω-conotoxin
MVIIA (30-300pmol/site, i.t.) inhibited 89±20% (Imax) of themechanical
hyperalgesia induced by a single injection of paclitaxel (1 mg/kg, i.p.),
with an estimated ED50 value (95% conﬁdence limits) of 94
(52–170) pmol/site (Fig. 3A). Statistically signiﬁcant antinociceptive
effect was found from 15 to 240 min post-administration (Fig. 3B).
When administered at chronic painful stage, the ω-conotoxin MVIIA
exhibited the same effectiveness and time-course observed in the acute
stage, inhibiting up to 100% (Imax) of the mechanical hyperalgesia from
15 to 240 min (Fig. 3D), but showed greater potency, with ED50value
(95% conﬁdence limits) of 5 (2–12)pmol/site (Fig. 3C). Likewise, Phα1β
(10-300 pmol/site) inhibited both acute (Imax = 100%) and chronic
(Imax = 81 ± 10%) mechanical hyperalgesia from 15 to 240 post-
administration (Fig. 3E-H), but no difference in its potency was found
between acute and chronic stage (ED50 value [95% conﬁdence limits] of
70 [33–140] pmol/site and 100 [60–160] pmol/site in acute and chronicstage, respectively). Neither ω-conotoxin MVIIA nor Phα1β altered the
normal mechanical sensitivity of control rats (data not shown).3.2. Adverse effects ofω-conotoxin MVIIA and Phα1β on acute and chronic
painful stages induced by paclitaxel
The ω-conotoxin MVIIA (10-100 pmol/site) induced signiﬁcant
adverse effects, such as serpentine tail movements, body shaking, and
dynamic allodynia. All doses of ω-conotoxin MVIIA elicited adverse
effects in acute and chronic painful stage, but a higher frequency
was observed when injected at chronic stage (Table 1). The estimated
TD50 value (95% conﬁdence limits) and therapeutic index (TD50/ED50)
of ω-conotoxin MVIIA were 26 (16–43) pmol/site and 0.3, in the acute
painful stage, and 22 (15–33) pmol/site and 4.4 in the chronic painful
stage. On the other hand, Phα1β (30-300 pmol/site) produced
minor adverse effects when injected at acute or chronic painful stage
(Table 1). Dynamic allodynia was observed only after the highest dose
tested (300pmol/site), hindering the estimation of the TD50.
Fig. 3.Antinociceptive effect of w-conotoxinMVIIA and Pha1b on paclitaxel- induced acute and chronicmechanical hyperalgesia. Dose-response curve and time-course effect produced by
ω-conotoxinMVIIA (30-300 pmol/site, i.t.) - (A and B) - and Phα1β; (10-300 pmol/site, i.t.) - (E and F) - on acutemechanical hyperalgesia induced by a single administration of paclitaxel
(PAC - 1 mg/kg, i.p.). Dose-response curve and time-course effect produced by ω-conotoxin MVIIA (3-30 pmol/site, i.t.) - (C and D) -and Phα1β (30-300 pmol/site, i.t.) - (G and H) - on
chronic mechanical hyperalgesia induced by 4 injections of paclitaxel (PAC - 1+1+1+1mg/kg, i.p., in alternate days). The effects are expressed as PWT (g). In dose-response curves the
PWTwas calculated at 60min post-drug treatment. B in the x axis denotes the baseline PWTbefore paclitaxel treatment. Each column or point represents themean of 5-7 rats, and vertical
lines show the SEM. Statistical analysis was performed using 1-way analysis of variance (ANOVA) followed by Student-Newman-Keuls posttest (A, C, E and G) or by 2-way ANOVA
followed by Bonferroni’s posttest (B, D, F and H); #Pb0.05, ##Pb0.01, ###Pb0.001 denote the signiﬁcance level in comparison to PBS-treated group (control group); ⁎Pb0.05,
⁎⁎Pb0.01,⁎⁎⁎Pb0.001 denote the level of signiﬁcance in comparison to baseline PWT before paclitaxel treatment.
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Table 1
Adverse effects assessment of ω-conotoxin MVIIA and Phα1β at acute and chronic painful stage induced by paclitaxel.
Drug Dose (pmol/site, i.t.b) Adverse effect
Serpentine tail/body shake Dynamic allodynia Score point
Acute Chronic Acute Chronic Acute Chronic
aPBS – 0/6 0/7 0/6 0/7 0 0
Phα1β 30 0/6 0/6 0/6 0/6 0 0
100 0/6 0/7 3/6 3/7 0.0 (0.0-1.0) (0.0-1.0)
300 0/7 0/6 5/7⁎ 5/6⁎⁎ 1.0 (0.0-1.0) 1.0 (0.75-1.0)
MVIIA 10 4/6⁎ 5/6⁎⁎ 3/6 5/6⁎⁎ 3.5 (1.75-4.0) 2.0 (0.75-2.25)⁎
30 5/7⁎ 8/8⁎⁎⁎ 4/7⁎ 8/8⁎⁎⁎ 4.0 (3.0-5.0)⁎ 5.0 (4.0-6.5)⁎⁎
100 6/7⁎⁎ 7/7⁎⁎⁎ 5/7⁎⁎ 7/7⁎⁎⁎ 6.0 (4.25-7.0)⁎⁎⁎ 5.0 (5.0-7.0)⁎⁎⁎
Data presented as number of rats affected/number of rats injectedwere analyzed byχ2 test. Score points, expressed asmedian± interquartile range, were analyzed using Kruskal-Wallis
non-parametric test (n= 5-7).
a PBS, phosphate-buffered saline.
b i.t., intrathecal.
⁎ P b 0.05 denote the signiﬁcance levels in comparison to PBS-treated group.
⁎⁎ P b 0.01 denote the signiﬁcance levels in comparison to PBS-treated group.
⁎⁎⁎ P b 0.001 denote the signiﬁcance levels in comparison to PBS-treated groups.
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mechanical hyperalgesia induced by paclitaxel
In our experimental conditions, of all rats treated with paclitaxel,
32 ± 8% did not show mechanical hyperalgesia neither at acute nor
at chronic painful stage. From those rats that showed mechanical
hyperalgesia (67 ± 8%), all of them showed it at chronic stage. Of
rats showing chronic mechanical hyperalgesia, 44 ± 5% also showed
mechanical hyperalgesia at acute stage. Notably, all animals affected
by acute pain also showed mechanical hyperalgesia at chronic stage.
Moreover, rats from the acute pain affected group (mean PWT of
67.1 ± 10.6 g at baseline and 21.8± 6.3 24 h after paclitaxel) showed
greater hyperalgesia at chronic painful stage than acute pain non-
affected rats (mean PWT of 8.1 ± 0.5 g for acute pain affected group
and 18.5 ± 4.7 for acute pain non-affected group after 15 days of the
ﬁrst paclitaxel injection — Fig. 4A).
We therefore investigatedwhether the administration ofω-conotoxin
MVIIA and Phα1β at acute painful stage (24 h after the ﬁrst paclitaxel
injection) affect the mechanical hyperalgesia at the chronic painful
stage (15days after the ﬁrst paclitaxel injection). Intrathecal treatment
of acute pain affected rats with ω-conotoxin MVIIA (300 pmol/site)
and Phα1β (300 pmol/site) at acute stage prevented the further
intensiﬁcation of mechanical hyperalgesia at chronic stage (mean
PWT of 8.3 ± 1.2, 21.4 ± 5.0, and 21.8 ± 3.3 g for PBS-treated group,
ω-conotoxin MVIIA-treated group and for Phα1β-treated group,
respectively; Pb0.05, 1-way ANOVA — Fig. 4B).
4. Discussion
Most of patients complain of pain at the early or later stage of
paclitaxel treatment (Polomano et al., 2001; Polomano and Bennett,
2001; Loprinzi et al., 2007; Reeves et al., 2012). However, no standard
therapy has been established to manage the acute or the chronic
neuropathic pain related to paclitaxel. In the present study, we evaluated
the analgesic potential of two N-type c blockers,ω-conotoxin MVIIA and
Phα1β, on an experimental model of paclitaxel-induced acute and
chronic pain. We showed that ω-conotoxin MVIIA and Phα1β reduced
the acute and the chronic mechanical hyperalgesia induced by paclitaxel,
but Phα1β showed superior therapeutic index than ω-conotoxin MVIIA.
We also showed a positive relation between the development of the
acute pain and the worsening of chronic pain induced by paclitaxel that
can be prevented by both VGCC blockers.
The paclitaxel-associated acute pain syndrome is a severe and
debilitating condition, described in up to 58% of patients (Loprinzi
et al., 2007, 2011). Although frequent, most pre-clinical studies have
focused on chronic neuropathic pain induced by paclitaxel, overlookingthe acute pain. Interesting, by applying a 4-day injection protocol of
paclitaxel treatment, known to cause a chronic painful neuropathy
(Polomano et al., 2001), we observed the development of mechanical
hyperalgesia after the ﬁrst injection of paclitaxel in 44% of the rats
treated. A single injection of paclitaxel inducedmechanical hyperalgesia
after 24 h, which was no longer detected at 48 h. Likewise, in humans
the acute pain symptoms usually begin within 1 to 2days of paclitaxel
administration (Loprinzi et al., 2007), demonstrating that this is a
suitable model to study the acute pain induced by paclitaxel.
Recent evidences have shown that patients under paclitaxel treatment
who experience intense pain following the ﬁrst cycle of administration
develop a more severe peripheral neuropathy in a later stage (Loprinzi
et al., 2011; Reeves et al., 2012), suggesting that the acute pain induced
by paclitaxel is related to the degree of pain associated to a posterior
nerve injury. In addition, other studies have shown that although the
neurotoxicity produced by paclitaxel is cumulative, the onset of sensory
symptoms may begin within 24–72 h following the ﬁrst administration
(Holmes et al., 1991; Rowinsky et al., 1993). In our study, while some
rats did not developed acute mechanical hyperalgesia after the ﬁrst
paclitaxel administration (56%), all rats that developed it also showed
mechanical hyperalgesia at chronic stage. Interesting, those rats that
developed acute pain showed a more intense mechanical hyperalgesia
at chronic stage. Thus, it seems that the acute pain is related to the
severity of the chronic pain symptoms. Therefore, the prophylactic
treatment at acute pain stage might prevent the worsening of chronic
painful symptoms. In agreement, we showed that administration of
ω-conotoxin MVIIA or Phα1β not only reduced the acute mechanical
hyperalgesia induced by paclitaxel but also prevented the worsening
of the associated chronic pain.
The paclitaxel-induced acute pain has been attributed to the sen-
sitization of nociceptors (Loprinzi et al., 2007). However, the molecular
mechanisms involved in such sensitization are still unclear. The N-type
VGCC are highly expressed on nociceptor terminals in laminae I and II of
the dorsal horn of the spinal cord, where theymediate calcium-induced
synaptic vesicle release (Perret and Luo, 2009; Zamponi et al., 2009).
Through spinal glutamate release, N-type VGCCs play an important
role in regulating neuronal excitability and nociceptive transmission,
being prominently involved in the transduction of acute pain signals
(Snutch, 2005). Both the ω-conotoxin MVIIA and the Phα1β have
shown to inhibit calcium inﬂux and glutamate release from spinal
cord of rats following acute pain stimulus (Souza et al., 2008). In this
study, we showed that the spinal injection of both VGCC blockers
reduced the acute mechanical hyperalgesia induced by paclitaxel,
supporting the involvement of N-type VGCC in nociceptor sensitization
following paclitaxel injection. In accordance, there are reports that the
anticonvulsant gabapentin, which inhibits VGCC activity by binding to
Fig. 4. Relation between the presence of acute mechanical hyperlagesia and the degree of
chronicmechanical hyperalgesia induced by paclitaxel. Comparison of chronicmechanical
hyperalgesia between acute pain-affected group and acute pain non-affected group (A).
Effect of ω-conotoxin MVIIA (300 pmol/site, i.t.) and Phα1β (300 pmol/site) on acute
and chronic pain induced by paclitaxel (PAC- 1+1+1+1 mg/kg, i.p., in alternate days)
in acute-pain affected rats (B). Acute and chronicmechanical hyperalgesiawere evaluated
24 h or 15 days after the ﬁrst paclitaxel injection. The data displayed in A correspond to
PBS-treated rats. The effects are expressed as PWT (g). B in the x axis denote the baseline
PWT before paclitaxel treatment. Each column represents the mean of 5-8 rats, and
vertical lines show the SEM. Statistical analysis was performed using a 1-way analysis of
variance (ANOVA) followed by Student-Newman-Keuls posttest; ⁎Pb0.05, ⁎⁎Pb0.01,
⁎⁎⁎Pb0.001 denote the level of signiﬁcance in comparison to baseline PWT before
paclitaxel treatment; xPb0.05 denotes the signiﬁcance level in comparison to acute pain
affected group; #Pb0.05 denotes the signiﬁcance level in comparison to PBS-treated
group; +Pb0.05 denotes the signiﬁcance level in comparison to PBS-treated group at
acute stage (24 hours after PAC).
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associated acute pain in patients (Garrison et al., 2003).
Several studies have highlighted the involvement of VGCC in the
chronic neuropathic pain induced by paclitaxel. TheN-typeVGCC blocker,
NMED-126, reduces the chronic neuropathic pain induced by paclitaxel in
rats (Xiao et al., 2007). Using the patch clamp technique, Kawakami et al.
(2012), demonstrated that paclitaxel treatment (4mg/kg, i.p., injected in
rats in 4 alternate days) increases VGCC current in small- and medium-
diameter DRG neurons after 7 days of the ﬁrst injection. Furthermore,
both the increase in VGCC currents and the mechanical hyperlagesia
induced by paclitaxel were inhibited by gabapentin (Kawakami et al.,
2012). Similarly, here we showed that the VGCC blockers ω-conotoxin
MVIIA and Phα1β reduced the mechanical hyperalgesia of ratsundergoing chronic neuropathic pain induced by paclitaxel. Interestingly,
the ω-conotoxin MVIIA reduced both the acute and the chronic pain
induced by paclitaxel with a similar efﬁcacy, but it showed a higher
potency in the chronic neuropathic painful stage. It has been shown
that in neuropathic states the high frequency of ﬁber activation
produces a dynamic change in the VGCC conformational state, which
switch between resting, activated, and inactivated (Winquist et al.,
2005). Depending on the VGCC conformational state, the afﬁnity of
some VGCC blockers are improved, as occurs with some ω-conotoxins,
which exhibit higher potency when binding to the inactivated
state of N-type VGCC (Stocker et al., 1997). Although ω-conotoxin
MVIIA can block N-type VGCC irrespective of the conformational state
of the channel, the N-type VGCC can assume two conformations upon
ω-conotoxin MVIIA binding, which differ in their stability (Feng et al.,
2003). For this reason, we believe that in the chronic neuropathic
stage induced by paclitaxel the N-type VGCC is in a conformational
state that favors the stability of ω-conotoxin MVIIA binding, increasing
the ω-conotoxin MVIIA afﬁnity and therefore its potency.
The ω-conotoxin MVIIA has received particular notoriety because its
synthetic version ziconotide (Prialt®) is currently used to treat severe
refractory pain (Staats et al., 2004). However, serious adverse effects
have been reported following ziconotide administration (Staats et al.,
2004; Ayuga-Loro et al., 2011). Here, we showed for the ﬁrst time that
ω-conotoxin MVIIA is efﬁcacious against experimental paclitaxel pain
model. On the other hand, the rats injected with ω-conotoxin MVIIA
showed severe motor and sensorial adverse effects. Unlike ω-conotoxin
MVIIA, the Phα1β elicited minimal adverse effects at the highest dose
tested. Although both Phα1β and ω-conotoxin MVIIA inhibit N-type
calcium currents (Kristipati et al., 1994; Vieira et al., 2005; Wang et al.,
1998), it is possible that they do not share identical docking sites on the
N-type VGCC, as described for the ω-conotoxins MVIIA and GVIA (Feng
et al., 2003). A probable difference in the binding sites of both VGCC
blockers would explain the difference in potency of ω-conotoxin MVIIA,
but not of Phα1β, in chronic painful stage as well.
4.1. Concluding remarks
In the present studywe showed evidences that both acute and chronic
pain induced by paclitaxel can be reduced by Phα1β and ω-conotoxin
MVIIA, and that the administration of both N-type VGCC blockers at the
acute painful stage can prevent the worsening of pain in the chronic
neuropathic stage. Furthermore, Phα1β exhibited superior therapeutic
proﬁle than ω-conotoxin MVIIA. Taken together, our data support
the involvement of N-type VGCCs in pain sensitization induced by
paclitaxel and point out the potential of Phα1β as a safer alternative
than ω-conotoxin MVIIA to treat the pain related to paclitaxel.
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